Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatitis B/D Entry Inhibitor & Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC10A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Cell Line | SLC10A1 (NTCP) Full-Length Lentivirus; HEK293 Expressed (Native Glycosylation), Sequence Verified, High Titer (>1×10⁸ TU/mL). For stable cell line generation preserving complex multi-pass conformation. | View SLC10A1 Products |
| Gene Delivery | SLC10A1 Promise-ORF / Lentivirus; Full-length ORF for stable HepG2/HEK293 cell line construction. | View SLC10A1 Products |
| Benchmark Ab/Peptide | Anti-SLC10A1 (Myrcludex B/Bulevirtide Sequence Reference); Recombinant positive control for entry inhibition assays. | View SLC10A1 Products |
| Validator | SLC10A1 siRNA Set; For knockdown verification and specificity control. | View SLC10A1 Products |
| Related Target A | SLC10A2 (ASBT/IBAT); Ileal bile acid transporter; critical for selectivity screening and enterohepatic circulation studies. | View SLC10A2 Products |
| Related Target B | SLC10A6 (NTCP-L/SOAT); Testis-enriched paralog; evaluate subfamily off-target binding risks. | View SLC10A6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation (Multi-pass Membrane Protein) | Lentivirus-mediated stable cell lines ensure functional structural integrity for binding assays. |
| Distinguishing Viral Entry vs. Bile Acid Transport | High-fidelity cellular models enabling dual-functional screening (viral pseudotype entry & substrate uptake). |
| Species Cross-Reactivity (Human vs. Cyno vs. Mouse) | Ortholog Lentivirus Panel available (Human/Mouse/Cyno) with >95% sequence identity verification; enables preclinical translation. |
| SLC10 Family Selectivity (A1 vs. A2 vs. A6) | Homolog panel (SLC10A1/A2/A6) lentiviruses for strict counter-screening; sequence-verified by NGS. |
| Lack of Controls / False Positives | Clinical Benchmark binders and validated siRNA included for baseline calibration and specificity checks. |
Live SLC10A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SLC10A1 (NTCP) therapeutic landscape is dominated by the first-in-class entry inhibitor Bulevirtide (Hepcludex/Myrcludex B), approved for Hepatitis D (HDV) and in development for Hepatitis B (HBV). As the pioneer peptide drug targeting viral entry reaches commercialization, the competitive horizon is shifting toward small-molecule NTCP antagonists with improved oral bioavailability and next-generation entry inhibitors for combination therapy. Concurrently, metabolic disease indications are emerging: NTCP inhibition shows promise in cholestatic disorders and NASH by modulating bile acid flux. The next wave of R&D targets allosteric modulators that block viral entry without completely disrupting physiological bile acid transport, requiring sophisticated functional assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Entry Inhibitor Peptide | Gilead Sciences, Hepion Pharmaceuticals | HDV, HBV | Cell-based HBV entry assay (Need full-length NTCP stable cell line) |
| Small Molecule Antagonist | Roche, Enanta Pharmaceuticals | NASH, Cholestasis | Taurocholate uptake inhibition (Need functional transport assay) |
| Monoclonal Antibody | Academic/Stealth Biotech | Viral Hepatitis | Surface epitope binding (Need native conformation lentivirus) |
| siRNA Combination | Dicerna, Alnylam | HBV Functional Cure | NTCP knockdown validation (Need validated siRNA controls) |
Key Mutations and Functional Variants
Key mutations in SLC10A1 affect taurocholate transport and viral entry. Notable variants include:
- rs200758433: Decreased function in taurocholate transport (UniProt VAR_085560).
- rs536458730: Decreased function in taurocholate transport (UniProt VAR_085561).
- rs111885789: Decreased function in taurocholate transport (UniProt VAR_085562).
- p.Ser267Phe: Affects glycosylation and membrane localization.
- p.Arg105Ala: preS1 binding defective mutant, useful as a mechanism control.
These variants are critical for understanding resistance mechanisms and designing next-generation inhibitors that can overcome reduced drug affinity.
Molecular Differentiation & Assay Strategy
To develop best-in-class SLC10A1 inhibitors, key differentiation factors include:
- Binding Mode Specificity: Distinguish competitive inhibition (competing with preS1) from non-competitive allosteric modulation. Assay strategy: dual-readout system using radiolabeled taurocholate (³H-TC) uptake and fluorescent preS1 peptide binding.
- Subfamily Selectivity: Ensure no cross-reactivity with SLC10A2 (ASBT) or SLC10A6 (SOAT) to avoid intestinal toxicity. Assay strategy: triple screening panel with SLC10A1/A2/A6 lentivirus cell lines.
- Cross-Species Translation: Human NTCP inhibitors often inactive on mouse NTCP (key difference: human Lys110 vs. mouse Gly). Assay strategy: Human/Cyno/Mouse triple stable cell lines on a NTCP-KO background.
- Kinetics & Internalization: NTCP is a recycling transporter; drug binding internalization dynamics affect duration. Assay strategy: antibody feeding assay with confocal microscopy or pH-sensitive dye labeling.
TarMart Solution: Full-length membrane-integrated expression via 3rd generation lentivirus (CMV or CAG promoter) ensures correct multi-pass domain insertion. High-titer preparations (>10⁸ TU/mL) with NGS sequence verification. Multi-species ortholog panel (Human, Cyno, Mouse) with key binding domain sequence alignment. Validated siRNA pool (targeting exons 3-4 junction) for >70% mRNA reduction. Mutant library support (e.g., p.Ser267Phe, p.Arg105Ala) for mechanism controls.